MAP2K1 and cystic fibrosis: To test the hypothesis that MEK1/2 inhibitor compounds would reduce production of pro-IL-1β and secretion of IL-8, CF macrophages were stimulated with P. aeruginosa LPS in media containing vehicle or one of the MEK1/2 inhibitor compounds, PD0325901, Trametinib, or CI-1040.